VVY

Vivoryon Therapeutics reported H1 2026 results with zero revenue, a net loss of EUR 3.4M (improved…

Traders should monitor for any definitive licensing agreement or equity financing announcement, as the company's cash runway extends only into Q4 2026. The advanced term sheet negotiations provide a…

Vivoryon Therapeutics N.V. announced it will report its full-year 2026 results on August 6, 2026.

Vivoryon reported Q1 2026 results with no revenue, a net loss of EUR 1.8M (improved from EUR 2.5M…

Monitor partnership announcements or financing events as the primary catalyst. The cash runway into Q4 2026 provides a timeline for deal-making; failure to secure funding before then would risk…

Vivoryon Therapeutics N.V. announced it will report its Q1 2026 results on June 11, 2026.